Table 1.
Clinico-pathological characteristics of the patients investigated in the present study (Espinoza-Sánchez et al. 2019)
| Parameter | Cohort | Proportion |
|---|---|---|
| Array platform | HGU133A | 52.10% |
| HGU133A plus 2.0 | 47.90% | |
| ER status | ER-positive | 76.40% |
| ER-negative | 23.65% | |
| HER2 status | HER2-positive | 17.70% |
| HER2-negative | 82.30% | |
| Lymph node status | Node positive | 39.20% |
| Node negative | 60.80% | |
| Grade | Grade 1 | 14.80% |
| Grade 2 | 42.30% | |
| Grade 3 | 42.80% | |
| Molecular subtype (St. Gallen) | TNBC | 17.10% |
| Luminal A | 48.60% | |
| Luminal B | 27.70% | |
| HER2-positive | 6.50% | |
| Molecular subtype (Pietenpol) | Basal-like 1 | 19.2% (within TNBC) |
| Basal-like 2 | 7.8% (within TNBC) | |
| Immunomodulatory | 23.4% (within TNBC) | |
| Mesenchymal | 18.4% (within TNBC) | |
| Mesenchymal stem-like | 9.2% (within TNBC) | |
| Luminal androgen-receptor | 22% (within TNBC) | |
| Age | Mean | 53.6 years |
| Median | 53 years | |
| Range | 24–93 years | |
| Relapse-free survival | Follow-up time (months) | 72.8 ± 46.6 |
| The proportion of events (relapse) | 32% | |
| Overall survival | Follow-up time (months) | 84.8 ± 47.8 |
| The proportion of events (death) | 25% |
TNBC triple-negative breast cancer